S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

GeoVax Labs Stock Forecast, Price & News

+0.31 (+7.67 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $4.35
50-Day Range
MA: $5.57
52-Week Range
Now: $4.35
Volume960,575 shs
Average Volume2.37 million shs
Market Capitalization$19.13 million
P/E RatioN/A
Dividend YieldN/A
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Vaxeal Holding SA; Virometix AG; Geneva Foundation; Enesi Pharma; UCSF; BravoVax; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.


GeoVax inks licensing pact with NIH for COVID-19 vaccine
October 26, 2020 |  seekingalpha.com
GeoVax shares rise on NIH vaccine deal
October 26, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GOVX
Phone(678) 384-7220
Year FoundedN/A



Sales & Book Value

Annual Sales$1.18 million
Book Value($233.94) per share


Net Income$-2,370,000.00
Net Margins-120.26%


Market Cap$19.13 million
Next Earnings Date3/24/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

0.70 out of 5 stars

Medical Sector

1242nd out of 1,972 stocks

Pharmaceutical Preparations Industry

559th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.31 (+7.67 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GOVX News and Ratings via Email

Sign-up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

GeoVax Labs (NASDAQ:GOVX) Frequently Asked Questions

Is GeoVax Labs a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GeoVax Labs in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GeoVax Labs stock.
View analyst ratings for GeoVax Labs
or view top-rated stocks.

What stocks does MarketBeat like better than GeoVax Labs?

Wall Street analysts have given GeoVax Labs a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GeoVax Labs wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting GeoVax Labs?

GeoVax Labs saw a decline in short interest in the month of January. As of January 29th, there was short interest totaling 384,200 shares, a decline of 20.0% from the January 14th total of 480,300 shares. Based on an average trading volume of 2,240,000 shares, the short-interest ratio is currently 0.2 days. Approximately 8.8% of the shares of the stock are sold short.
View GeoVax Labs' Short Interest

When is GeoVax Labs' next earnings date?

GeoVax Labs is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for GeoVax Labs

How were GeoVax Labs' earnings last quarter?

GeoVax Labs, Inc. (NASDAQ:GOVX) released its earnings results on Monday, August, 10th. The company reported ($0.03) earnings per share (EPS) for the quarter. The firm earned $0.44 million during the quarter. GeoVax Labs had a negative trailing twelve-month return on equity of 320.30% and a negative net margin of 120.26%.
View GeoVax Labs' earnings history

How has GeoVax Labs' stock been impacted by COVID-19 (Coronavirus)?

GeoVax Labs' stock was trading at $0.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GOVX stock has increased by 1,453.6% and is now trading at $4.35.
View which stocks have been most impacted by COVID-19

What price target have analysts set for GOVX?

1 Wall Street analysts have issued twelve-month price targets for GeoVax Labs' stock. Their forecasts range from $8.00 to $8.00. On average, they expect GeoVax Labs' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 83.9% from the stock's current price.
View analysts' price targets for GeoVax Labs
or view top-rated stocks among Wall Street analysts.

Who are GeoVax Labs' key executives?

GeoVax Labs' management team includes the following people:
  • Mr. David Alan Dodd, Chairman, Pres & CEO (Age 71, Pay $250.92k)
  • Dr. Harriet Latham Robinson, Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board (Age 83)
  • Mr. Mark W. Reynolds CPA, CPA, CFO & Corp. Sec. (Age 59, Pay $240.02k)
  • Dr. Mark J. Newman, Chief Scientific Officer (Age 66)

Who are some of GeoVax Labs' key competitors?

What is GeoVax Labs' stock symbol?

GeoVax Labs trades on the NASDAQ under the ticker symbol "GOVX."

Who are GeoVax Labs' major shareholders?

GeoVax Labs' stock is owned by many different institutional and retail investors. Top institutional shareholders include Welch & Forbes LLC (0.73%) and Virtu Financial LLC (0.29%). Company insiders that own GeoVax Labs stock include David A Dodd, Mark Reynolds and Randal D Chase.
View institutional ownership trends for GeoVax Labs

Which major investors are buying GeoVax Labs stock?

GOVX stock was acquired by a variety of institutional investors in the last quarter, including Welch & Forbes LLC, and Virtu Financial LLC. Company insiders that have bought GeoVax Labs stock in the last two years include David A Dodd, Mark Reynolds, and Randal D Chase.
View insider buying and selling activity for GeoVax Labs
or or view top insider-buying stocks.

How do I buy shares of GeoVax Labs?

Shares of GOVX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GeoVax Labs' stock price today?

One share of GOVX stock can currently be purchased for approximately $4.35.

How much money does GeoVax Labs make?

GeoVax Labs has a market capitalization of $19.13 million and generates $1.18 million in revenue each year.

How many employees does GeoVax Labs have?

GeoVax Labs employs 6 workers across the globe.

What is GeoVax Labs' official website?

The official website for GeoVax Labs is www.geovax.com.

Where are GeoVax Labs' headquarters?

GeoVax Labs is headquartered at 1900 LAKE PARK DRIVE SUITE 380, SMYRNA GA, 30080.

How can I contact GeoVax Labs?

GeoVax Labs' mailing address is 1900 LAKE PARK DRIVE SUITE 380, SMYRNA GA, 30080. The company can be reached via phone at (678) 384-7220 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.